Advanced in Plasmacytoma

Dr. Dan Vogl

Hematology
Penn Medicine
Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
Advanced in Plasmacytoma
Penn Medicine
Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dan Vogl is a Hematologist in Philadelphia, Pennsylvania. Dr. Vogl is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vogl is currently accepting new patients.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
NewYork-Presbyterian / Weill Cornell Medical Center
Residency
NewYork-Presbyterian/Columbia University Medical Center
Specialties
Hematology
Licenses
Internal Medicine in PA
Board Certifications
Hematology, 2008
Fellowships
Hospital of the University of Pennsylvania
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, Philadelphia, PA 19104
Call: 215-615-5858

Additional Areas of Focus

Dr. Vogl has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Multiple Myeloma
Waldenstrom Macroglobulinemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma
Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma
Enrollment Status: Terminated
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Tasquinimod, Ixazomib, Lenalidomide, and Dexamethasone Chemotherapy
Study Phase: Phase 1
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 26, 2022
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Biological
Study Drug: CAR2 Anti-CD38 A2 CAR-T Cells
Study Phase: Phase 1
View 6 Less Clinical Trials

94 Total Publications

Outcomes of relapse after teclistamab therapy in multiple myeloma.
Outcomes of relapse after teclistamab therapy in multiple myeloma.
Journal: Blood cancer journal
Published: August 14, 2025
View All 94 Publications
Similar Doctors
Advanced in Plasmacytoma
Dr. Edward A. Stadtmauer
Hematology
Advanced in Plasmacytoma
Dr. Edward A. Stadtmauer
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edward Stadtmauer is a Hematologist in Philadelphia, Pennsylvania. Dr. Stadtmauer is rated as an Elite provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Stadtmauer is currently accepting new patients.

Advanced in Plasmacytoma
Dr. Adam Waxman
Hematology
Advanced in Plasmacytoma
Dr. Adam Waxman
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Waxman is a Hematologist in Philadelphia, Pennsylvania. Dr. Waxman is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Splenectomy. Dr. Waxman is currently accepting new patients.

Simi M. Rai
Advanced in Plasmacytoma
Dr. Simi M. Rai
Hematology | Oncology
Advanced in Plasmacytoma
Dr. Simi M. Rai
Hematology | Oncology

LVH Hematology Oncology-1240 Cedar Crest

1240 S Cedar Crest Blvd, Suite 401, 
Allentown, PA 
 (46.2 miles away)
610-402-7880
Languages Spoken:
English, Hindi
See accepted insurances
Offers Telehealth

Simi Rai is a Hematologist and an Oncologist in Allentown, Pennsylvania. Dr. Rai is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, and Paget Disease of the Breast.

VIEW MORE PLASMACYTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vogl's expertise for a condition
ConditionClose
  • Elite
  • Multiple Myeloma
    Dr. Vogl is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Distinguished
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
    Dr. Vogl is
    Distinguished
    . Learn about Monoclonal Gammopathy of Undetermined Significance (MGUS).
    See more Monoclonal Gammopathy of Undetermined Significance (MGUS) experts
  • Primary Amyloidosis
    Dr. Vogl is
    Distinguished
    . Learn about Primary Amyloidosis.
    See more Primary Amyloidosis experts
  • Relapsed Refractory Multiple Myeloma (RRMM)
    Dr. Vogl is
    Distinguished
    . Learn about Relapsed Refractory Multiple Myeloma (RRMM).
    See more Relapsed Refractory Multiple Myeloma (RRMM) experts
  • Schnitzler Syndrome
    Dr. Vogl is
    Distinguished
    . Learn about Schnitzler Syndrome.
    See more Schnitzler Syndrome experts
  • Smoldering Multiple Myeloma
    Dr. Vogl is
    Distinguished
    . Learn about Smoldering Multiple Myeloma.
    See more Smoldering Multiple Myeloma experts
  • Advanced
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Vogl is
    Advanced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Vogl is
    Advanced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Cryoglobulinemia
    Dr. Vogl is
    Advanced
    . Learn about Cryoglobulinemia.
    See more Cryoglobulinemia experts
  • Familial Mixed Cryoglobulinemia
    Dr. Vogl is
    Advanced
    . Learn about Familial Mixed Cryoglobulinemia.
    See more Familial Mixed Cryoglobulinemia experts
  • Non-Hodgkin Lymphoma
    Dr. Vogl is
    Advanced
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Plasmacytoma
    Dr. Vogl is
    Advanced
    . Learn about Plasmacytoma.
    See more Plasmacytoma experts
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Vogl is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Vogl is
    Experienced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Vogl is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myelomonocytic Leukemia
    Dr. Vogl is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Agranulocytosis
    Dr. Vogl is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Aplastic Anemia
    Dr. Vogl is
    Experienced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Close
      0 / 1000

      Please provide us with the below insurance information:

              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.